Dose Escalation of Velcade Daily Dose in Patients With Solid Tumors
Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
VELCADE has demonstrated marked activity in haematological cancers leading to registration
(MM, MCL).
Currently only biweekly or weekly regimens have been explored. Key signalling pathways which
are aberrant in haematological cancers are also present in solid tumors.
VELCADE covers a broad spectrum of proteins, which are pivotal in carcinogenesis.VELCADE as a
single agent & in combination with chemotherapy in solid cancers has shown modest and real
anti-tumor activity but insufficient for Phase III development.
VELCADE PK exposure may be inadequate in solid tumors compared to "liquid cancers." VELCADE
daily low dose administration may allow a greater PK exposure to be achieved, which is
tolerated
Hypotheses:
VELCADE daily dosing (5-days on, 2-days off) is tolerable at biologically active doses
VELCADE daily dosing (5-days on, 2-days off) results in increased PK (AUC)/PD (20S proteasome
inhibition) VELCADE daily dosing (5-days on, 2-days off) with increased PK/PD results in
improved anti-tumor activity (Increased tolerable VELCADE AUC may potentially cross the
threshold required for clinically significant anti-tumor activity in solid cancers).
Some preclinical data suggest that: VELCADE daily dosing results in increased proteasome
inhibition in tumor tissues Combination of VELCADE + XRT/other daily dosing agent may have
increased anti-tumor activity compared to monotherapy alone.